

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### **Budesonide as a treatment for early COVID-19, cutaneous reactions to vaccines, medico-legal aspects of telehealth encounters**

#### **Peer reviewed journals featured:**

- Updated systematic reviews on:
  - The incubation period of COVID-19 [here](#)
  - Antibody responses following SARS-CoV-2 infection [here](#)
- A phase 2 randomised controlled trial on inhaled budesonide in the treatment of early COVID-19 [here](#) and associated commentary [here](#)
- Case reports of:
  - Cutaneous reactions after Moderna and Pfizer COVID-19 vaccination [here](#) and [here](#)
  - Prolonged anaphylaxis to Pfizer vaccine [here](#)
  - Poor humoral and T-cell responses after two injections of mRNA vaccine in kidney transplant recipients treated with belatacept [here](#)
- Ethics analysis on:
  - The World Health Organization allocation framework for COVAX [here](#)
  - Medico-legal implications of audio-visual recordings of telehealth encounters [here](#)
- Observational studies on
  - Humoral response after BNT162b2 (Pfizer) vaccination [here](#)
  - Mortality among US hospitalised patients with SARS-CoV-2 infection in 2020 [here](#)
  - The experience of Australian patients at high risk of poor health outcomes with telehealth [here](#)
- An editorial on vaccine nationalism and contractual discord regarding COVID-19 [here](#)
- Commentary on:
  - COVID-19 and global health [here](#)
  - China's COVID-19 vaccines [here](#)
  - Correlates of protection from SARS-CoV-2 infection [here](#)
  - The politicisation of ivermectin [here](#)
  - The role of MAIT cells in the association between COVID-19 severity and obesity [here](#)

#### **Letters and correspondence discussed:**

- Clofazimine as a potential treatment of COVID-19 [here](#)
- Variant B.1.1.7 (UK / Kent) among SARS-CoV-2 isolates in Toronto [here](#)

## Pre-peer review articles featured:

- A systematic review on long-term post-acute sequelae of SARS-CoV-2 infection [here](#)
- SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative healthcare workers in England [here](#)

## Guidance and reports

- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The World Health Organizations published its COVID-19 weekly epidemiological update [here](#)
- The Therapeutic Goods Administration released a safety advisory update on AstraZeneca COVID-19 vaccine regarding thrombosis with thrombocytopenia [here](#)

## News and blogs

- COVID-19 could become entrenched as a disease of poverty [here](#)
- Has Europe failed to protect its people from COVID-19? [here](#)
- Mapping outcomes of COVID-19 testing [here](#)
- Maintaining trust in the COVID-19 vaccine program in the UK [here](#)
- The lack of vaccine trial data creates another layer of inequality [here](#)
- A strategy to optimise global vaccination coverage [here](#)
- Scientists investigate how a COVID-19 vaccine could cause blood clots [here](#)
- Positive lateral flow results will again require confirmatory PCR testing in the UK [here](#)
- Issues with vaccine passports [here](#) and [here](#)

[Click here](#) to subscribe to the daily evidence digest.

### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern.